While our results show high interest in initiating WMMs, other surveys have suggested decreased interest based on the injection route of administration.24 Recent studies suggest variable adherence and continuation of incretin mimetics based on the type of WMM, indication (type 2 diabetes or weight management), effectiveness for weight loss, cost of medication, and access to continued insurance coverage.25,26,27,28 It remains unknown what percentage of older adults would initiate and continue incretin mimetic treatment if covered, and how this would affect projected costs. Here, GCG is linked to type 2 diabetes mellitus.